No Data
No Data
No Data
No Data
No Data
Press Release: Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- I
Dow JonesApr 25 04:01
Cantor Fitzgerald Inc.: Reiterated the Intra-Cellular Therapies (ITCI.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $120.00.
Cantor Fitzgerald Inc.: Reiterated the Intra-Cellular Therapies (ITCI.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $120.00.
Zhitong FinanceApr 24 22:01
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and maintains $120 price target.
BenzingaApr 24 21:57
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
TipRanksApr 24 20:50
Intra-Cellular Therapies Is Maintained at Buy by Canaccord Genuity
Intra-Cellular Therapies Is Maintained at Buy by Canaccord Genuity
Dow JonesApr 23 22:58
Canadian Investment Banking Group: Maintaining the Intra-Cellular Therapies (ITCI.US) rating, adjusted from buy to buy rating, and adjusted the target price from $100.00 to $107.00.
Canadian Investment Banking Group: Maintaining the Intra-Cellular Therapies (ITCI.US) rating, adjusted from buy to buy rating, and adjusted the target price from $100.00 to $107.00.
Zhitong FinanceApr 23 22:51
No Data
No Data